Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system
- PMID: 11322500
- DOI: 10.1385/endo:14:1:035
Growth hormone-releasing hormone and growth hormone secretagogue-receptor ligands: focus on reproductive system
Abstract
Growth hormone-releasing hormone (GHRH) and somatostatin are the most important hypothalamic neurohormones controlling growth hormone (GH) secretion. Several neurotransmitters and neuropeptides also play an important role in the control of GH secretion, mainly acting via modulation of GHRH and somatostatin. In the past two decades, particular attention has been given to a new family of substances showing a strong GH-releasing effect: GH secretagogues (GHSs). GHSs increase GH secretion in a dose- and age-related manner after iv and even oral administration. The endocrine effects of GHSs, are not fully specific for GH; they show, in fact, prolactin- (PRL), adenocorticotropic hormone- and cortisol-releasing effects. Specific GHS receptors are present in both the central nervous system and peripheral tissues, where they mediate several extraendocrine effects of GHSs. The isolation of these "orphan" receptors suggested the existence of an endogenous GHS-like ligand that could be represented by a recently discovered gastric peptide, named ghrelin. The interaction between GHSs and GHRH at the central level and in the pituitary gland, but not at peripheral level, has clearly been shown. Because GHRH and GHS receptors share the same localization in some peripheral tissues, they may have some interactions even at this level.
Similar articles
-
Biologic activities of growth hormone secretagogues in humans.Endocrine. 2001 Feb;14(1):87-93. doi: 10.1385/ENDO:14:1:087. Endocrine. 2001. PMID: 11322506 Review.
-
Endocrine activities of ghrelin, a natural growth hormone secretagogue (GHS), in humans: comparison and interactions with hexarelin, a nonnatural peptidyl GHS, and GH-releasing hormone.J Clin Endocrinol Metab. 2001 Mar;86(3):1169-74. doi: 10.1210/jcem.86.3.7314. J Clin Endocrinol Metab. 2001. PMID: 11238504 Clinical Trial.
-
Interactions of growth hormone secretagogues and growth hormone-releasing hormone/somatostatin.Endocrine. 2001 Feb;14(1):21-7. doi: 10.1385/ENDO:14:1:021. Endocrine. 2001. PMID: 11322498
-
Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans.Clin Endocrinol (Oxf). 2003 Jan;58(1):92-8. doi: 10.1046/j.1365-2265.2003.01680.x. Clin Endocrinol (Oxf). 2003. PMID: 12519418
-
Endocrine and non-endocrine activities of growth hormone secretagogues in humans.Horm Res. 1999;51 Suppl 3:9-15. doi: 10.1159/000053156. Horm Res. 1999. PMID: 10592438 Review.
Cited by
-
The traditional Japanese medicine Rikkunshito increases the plasma level of ghrelin in humans and mice.J Gastroenterol. 2010 Mar;45(3):300-7. doi: 10.1007/s00535-009-0166-z. Epub 2009 Dec 10. J Gastroenterol. 2010. PMID: 19997944 Clinical Trial.
-
Ageing, growth hormone and physical performance.J Endocrinol Invest. 2003 Sep;26(9):861-72. doi: 10.1007/BF03345237. J Endocrinol Invest. 2003. PMID: 14964439 Review.
-
Potential future options in the pharmacotherapy of female sexual dysfunction.World J Urol. 2006 Dec;24(6):630-8. doi: 10.1007/s00345-006-0121-z. World J Urol. 2006. PMID: 17048031 Review.
-
GHRH and reproductive systems: Mechanisms, functions, and clinical implications.Rev Endocr Metab Disord. 2025 Jun;26(3):507-524. doi: 10.1007/s11154-024-09931-8. Epub 2024 Nov 29. Rev Endocr Metab Disord. 2025. PMID: 39612161 Review.
-
Ghrelin antagonized 1-methyl-4-phenylpyridinium (MPP(+))-induced apoptosis in MES23.5 cells.J Mol Neurosci. 2009 Feb;37(2):182-9. doi: 10.1007/s12031-008-9162-7. Epub 2008 Dec 4. J Mol Neurosci. 2009. PMID: 19052922
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous